Navigation Links
OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
Date:7/14/2008

bination with docetaxel retreatment have indicated that OGX-011 may help restore tumor sensitivity to docetaxel and may improve overall survival for second-line therapy."

The planned initiation of this Phase 3 trial is supported by encouraging preliminary Phase 2 data that were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO). These preliminary data are derived from a Phase 2 study evaluating 42 patients with HRPC who had received first-line docetaxel therapy and required second-line chemotherapy: 22 patients were treated with mitoxantrone plus OGX-011 and 20 patients with docetaxel retreatment plus OGX-011. While follow up on surviving patients is still ongoing, the following preliminary findings were reported:

- Survival continued to be better than expected based on previously

published reports: With a median follow-up of 17.2 months following the

start of second-line chemotherapy, median survival has been estimated

at 11.4 months in the mitoxantrone plus OGX-011 group and 14.7 months

in the docetaxel retreatment plus OGX-011 group. These data compare

favorably with published results reporting median survivals at

approximately 10 months for HRPC patients receiving second-line

chemotherapy without OGX-011.

- In addition, average serum clusterin levels during treatment were

predictive of survival, with low-average levels predicting median

survival time of 14.7 months compared to high-average levels predicting

median survival time of 5.5 months. These data suggest that a reduction

in clusterin levels may improve survival.

About OGX-011

OGX-011 is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer indications and in response to many cancer treatments. Increased clusterin production is observed in many human cancers, including prostate, non-small c
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex increases economic interest in lead cancer drug OGX-011
2. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
9. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... Inclinix, Inc. a contract,research organization that hires ... new drugs, today announced restructuring of positions to,support ... of,40% in 2007 and the infusion of $10 ... Frontier Capital, a private equity firm., Diane ...
... SAN FRANCISCO, June 3 VIA Pharmaceuticals,(Nasdaq: ... development of,compounds for the treatment of cardiovascular disease, ... chief executive officer of VIA, and,James G. Stewart, ... a company update at the Seventh Annual Needham ...
... 3 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical Technology, Inc (OTC ... of plant extracts and pharmaceutical raw materials,for ... released an,update on its business following their ... "In the first quarter, sales of our ...
Cached Biology Technology:Inclinix Expansion Creates New Position and Promotions 2Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification 2
(Date:7/11/2014)... that cannabinoid receptor type 1 can inhibit ... and reduce neurotransmitter release. However, some scholars ... increase extracellular Ca2+ influx and increase neurotransmitter ... Tongji Hospital Affiliated to Tongji Medical College, ... used whole cell voltage-clamp and calcium imaging ...
(Date:7/10/2014)... Colo. , June 27, 2014  The ... the National Institute of Standards and Technology (NIST) ... of its academic research and forensic science expert ... The Board is an element of the NIST,s ... members are among the first appointments made to ...
(Date:7/10/2014)... N.Y. , July 2, 2014 It ... (ABD) to announce the appointment of the world-renowned Thoracic ... Board of Directors. Dr. Ginsburg, with over ... facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical ... Pacemaker since the late 1980,s and is considered an ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... to developing new antibiotics, and a technique called solid-state ... , That's the view of University of Michigan ... toward that goal March 3 at the annual meeting ... Ramamoorthy's research group is using solid-state NMR to explore ...
... Flavonoids, a group of compounds found in fruits and ... for their antioxidant activity, actually have little or no ... scientists in the Linus Pauling Institute at Oregon State ... human health, but for reasons that are quite different ...
... of the persistent riddles of the deadly 1918 Spanish ... varying severity. Why were some municipalities such as St. ... Philadelphia when both implemented similar public health measures? What ... by the National Institutes of Health (NIH), was not ...
Cached Biology News:Natural antibiotics yield secrets to atom-level imaging technique 2Natural antibiotics yield secrets to atom-level imaging technique 3Studies force new view on biology of flavonoids 2Studies force new view on biology of flavonoids 3Rapid response was crucial to containing the 1918 flu pandemic 2Rapid response was crucial to containing the 1918 flu pandemic 3Rapid response was crucial to containing the 1918 flu pandemic 4
... workstation is the simplest, easiest-to-use system ever ... liquid handling capabilities,into their labs, or groups ... routine applications on a separate instrument. Plate-handling ... even when you have thousands of ...
... has generated hybridomas against a large ... initiation, you are provided with personalized ... cell lines developed by Covance remain ... typical hybridoma development project has four ...
... cDNA normalization is essential for ... using high-throughput approaches, such as EST ... Most normalization methods are not well ... cDNA. The Evrogen TRIMMER kit, though, ...
... ENGENISTM (Entire Gene/cDNA or Isolated Sequence) siRNA ... quantitative approach for evaluation of a potential ... an efficient target for RNA interference (RNAi). ... not perfect, leaving the probability of selected ...
Biology Products: